Top Line Data for Jaguar Health's Pivotal Phase 3 OnTarget Trial for Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Therapy Forthcoming | Region

SAN FRANCISCO, CA / ACCESSWIRE / November 21, 2023 / Napo Pharmaceuticals (Napo), a Jaguar Health, Inc.(NASDAQ:JAGX) family company, today announced that the company has not yet been provided with

Related Keywords

Italy ,San Antonio ,Texas ,United States ,Milan ,Lombardia ,Italian ,Lisa Conte ,Jaguar Health Family Of Companies ,Jaguar Health ,Napo Pharmaceuticals ,Jaguar Health Inc ,Good Clinical Practice ,Antonio Breast Cancer ,Target Clinical ,Jaguar Health Family ,Napo Therapeutics ,Region ,